We are live on
!
Find out more
CA
Corriente Advisors Portfolio holdings
AUM
$9.53M
1-Year Est. Return
805.26%
This Fund
S&P 500
This Quarter
Est. Return
+82.51%
1 Year Est. Return
+805.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$154M
AUM Growth
+$61.7M
(+67%)
Cap. Flow
+$20.3M
Cap. Flow
% of AUM
13.14%
Top 10 Holdings %
Top 10 Hldgs %
95.94%
Holding
21
New
10
Increased
1
Reduced
4
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sonos
SONO
|
+$16.7M |
| 2 |
uniQure
QURE
|
+$10.6M |
| 3 |
Replimune Group
REPL
|
+$8.58M |
| 4 |
Ocular Therapeutix
OCUL
|
+$4.77M |
| 5 |
MAXR
Maxar Technologies Inc. Common Stock
MAXR
|
+$2.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$6.46M |
| 2 |
PVLA
Palvella Therapeutics
PVLA
|
+$4.42M |
| 3 |
Cue Biopharma
CUE
|
+$3.86M |
| 4 |
EPZM
Epizyme, Inc
EPZM
|
+$3.57M |
| 5 |
Schrodinger
SDGR
|
+$2.59M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 49.35% |
| 2 | Technology | 36.99% |
| 3 | Consumer Discretionary | 1.4% |
| 4 | Materials | 0.59% |
| 5 | Real Estate | 0.34% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MAXR
1
DELISTED
Maxar Technologies Inc. Common Stock
MAXR
| $34.1M | 22.11% |
1,900,000
+210,900
| +12% | +$2.73M |
|
|
RETA
2
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $23M | 14.91% |
147,500
-42,500
| -22% | -$6.46M |
|
|
3
Sonos
SONO
$1.8B
| $23M | 14.88% |
+1,570,000
| New | +$16.7M |
|
|
APTO
4
DELISTED
Aptose Biosciences, Inc.
APTO
| $17.5M | 11.33% |
6,158
-326
| -5% | -$1.05M |
|
|
5
Cue Biopharma
CUE
$131M
| $16.2M | 10.48% |
22,000
-5,333
| -20% | -$3.86M |
|
|
6
Replimune Group
REPL
$859M
| $12.1M | 7.81% |
+485,000
| New | +$8.58M |
|
|
7
uniQure
QURE
$2.77B
| $8.11M | 5.26% |
+180,000
| New | +$10.6M |
|
|
8
Ocular Therapeutix
OCUL
$1.96B
| $6M | 3.89% |
+720,000
| New | +$4.77M |
|
9
Celldex Therapeutics
CLDX
$2.77B
| $5.98M | 3.87% |
+460,000
| New | +$2.04M |
|
10
Tesla
TSLA
$1.43T
| $2.16M | 1.4% |
30,000
| – | – |
|
11
Arrowhead Research
ARWR
$10.5B
| $1.73M | 1.12% |
+40,000
| New | +$1.41M |
|
12
DiaMedica Therapeutics
DMAC
$393M
| $1.4M | 0.9% |
+201,248
| New | +$898K |
|
13
Pan American Silver
PAAS
$17.6B
| $912K | 0.59% |
+30,000
| New | +$712K |
|
14
Cardiff Oncology
CRDF
$60.2M
| $869K | 0.56% |
+173,361
| New | +$355K |
|
|
PVLA
15
Palvella Therapeutics
PVLA
$2.26B
| $837K | 0.54% |
3,375
-18,899
| -85% | -$4.42M |
|
|
RWT
16
Redwood Trust
RWT
$641M
| $525K | 0.34% |
+75,000
| New | +$370K |
|
|
17
Schrodinger
SDGR
$1.14B
| – | – |
-60,000
| Closed | -$2.59M |
|
|
VIRX
18
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| – | – |
-86,334
| Closed | -$1.25M |
|
|
BLU
19
DELISTED
BELLUS Health Inc.
BLU
| – | – |
-148,666
| Closed | -$1.48M |
|
|
EPZM
20
DELISTED
Epizyme, Inc
EPZM
| – | – |
-230,000
| Closed | -$3.57M |
|
Similar funds
SCM
FWM
TOPU
TGI
GIP
LCMP
SCM
TA
Corriente Advisors's Q2 2020 Portfolio in Review
As of Q2 2020, Corriente Advisors held 21 positions worth $154M, up 67% from $92.6M the previous quarter. Its ten largest holdings account for 96% of the portfolio.
Corriente Advisors deployed $20.3M of net new capital in Q2 2020, opening 10 new positions and adding to 1 existing holding. Its largest new stake was Sonos: 1,570,000 shares worth $23M.
By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 56% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $6.46M trimmed.
- Corriente Advisors's largest Q2 2020 buy was Sonos: 1,570,000 shares worth $23M.
- Corriente Advisors added most to Maxar Technologies Inc. Common Stock in Q2 2020, an estimated $2.73M increase.
- Corriente Advisors's biggest Q2 2020 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $6.46M.
- Corriente Advisors fully exited Epizyme, Inc in Q2 2020, selling an estimated $3.57M.
- Corriente Advisors's ten largest holdings make up 96% of its $154M portfolio in Q2 2020.
- Corriente Advisors opened 10 new positions and closed 5 in Q2 2020.
- Corriente Advisors's portfolio value rose 67% quarter-over-quarter to $154M.
Based on Corriente Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.